Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Gynecologic 1

Conditions

Breast Neoplasms 3Prostatic Neoplasms 2Leiomyosarcoma 2Uterine Neoplasms 1Triple Negative Breast Neoplasms 1Sarcoma 1Pathologic Complete Response 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Liposarcoma 1Hemangiosarcoma 1Colorectal Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Doxorubicin 25Gemcitabine 16Trabectedin 12Ifosfamide 12Radiotherapy 11Docetaxel 10Dacarbazine 8pazopanib 7Nivolumab 6Specimen Handling 5Biopsy 5liposomal doxorubicin 4Temozolomide 4pembrolizumab 3Sunitinib 3Sorafenib 3Radiation 3Magnetic Resonance Spectroscopy 3Filgrastim 3rucaparib 2pegfilgrastim 2olaratumab 2eribulin 2durvalumab 2cixutumumab 2cemiplimab 2brostallicin 2belinostat 2avelumab 2X-Rays 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leiomyosarcoma × Letrozole × Sarcoma × Clear all
NCT00414076 2018-11-20

Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma

M.D. Anderson Cancer Center

Phase 2 Terminated
9 enrolled 7 charts
GynecologicSarcoma

Leiomyosarcoma, Uterine Neoplasms

NCT00856050 2017-04-18

Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma

Dana-Farber Cancer Institute

Phase 2 Completed
27 enrolled 4 charts
Sarcoma

Leiomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡